I believe new, potential indications for Phase 2 trials will be announced post the FDA meeting. I expect trial design to be a key discussion point, both Phase 2 & 3. What I'd like to see, but I doubt will occur, is Neuren announcing in vitro results for Dementia and Parkinsons. I know we won't be completing Phase 2 trials for these two (we would need $billions), but that's not a concern for me. What I'd like us to do is remind the market, shareholders and any prospective big pharma of the positive results seen in mice in studies of 2591 conducted around 2006. I'm sure there are many here who don't know of this. If we can prove it in vitro as well as in mice, surely that would have the smart minds thinking of future opportunities? Again, I doubt this will happen, but if it was my business and my money and I was looking for catalysts for prospective purchasers, then I'd be going down that path.
NEU Price at posting:
$16.15 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)